The ASCENT trial has emerged as a pivotal study in the quest to optimize treatment for patients with EGFR-mutant locally advanced non-small cell lung cancer (NSCLC). Investigators have been exploring how to effectively integrate tyrosine kinase inhibitors (TKIs) into established treatment protocols. The findings from this phase 2 trial reveal both the challenges and potential for improving patient outcomes through the use of afatinib, a second-generation TKI.
Study Overview
The ASCENT trial, which concluded in December 2021, aimed to assess the safety and efficacy of afatinib in conjunction with concurrent chemoradiotherapy (cCRT) for patients diagnosed with locally advanced NSCLC. The trial’s design predated the widespread use of osimertinib, positioning afatinib as a crucial intervention in the treatment landscape for this patient group.
The study involved 19 participants, all with histologically confirmed, locally advanced stage III NSCLC harboring an activating EGFR mutation. The treatment regimen began with two cycles of daily oral afatinib at a dose of 40 mg. Patients who did not show disease progression then proceeded to receive cCRT, which included a combination of chemotherapy and radiation.
Treatment Protocol
The treatment protocol was meticulously structured. Patients underwent induction therapy with afatinib before moving on to cCRT, which consisted of a radiation dose ranging from 45 to 72 Gy, depending on whether the treatment was preoperative or definitive. Concurrent chemotherapy utilized cisplatin and pemetrexed, tailored to the setting of the radiation treatment.
The primary endpoint focused on the objective response rate, while secondary endpoints evaluated safety, operability post-induction therapy, progression-free survival (PFS), and overall survival (OS). The demographics of the study cohort revealed a median age of 56 years, with a significant majority being female and former tobacco users. The most prevalent mutation type was exon 19 deletion.
Key Findings
The ASCENT trial yielded compelling results. Following the induction phase, 10 patients underwent surgical procedures, resulting in significant pathologic responses, including one complete response in a patient who was initially deemed unresectable. The overall response rate to afatinib was recorded at 63%, indicating a robust reaction among participants.
Among the 19 patients, the median follow-up period was 5.04 years, showing promising survival metrics. Eight patients remained alive at the time of analysis, with a median PFS of 2.63 years and median OS of 5.76 years. Notably, three patients exhibited no signs of recurrence, highlighting the potential for long-term disease control.
Challenges and Side Effects
Despite positive outcomes, the ASCENT trial also underscored the complexities of managing treatment-related adverse events (AEs). Common grade 3 AEs included diarrhea, nausea, and rash, while grade 2 AEs such as pneumonitis were observed. Importantly, there were no reports of severe grade 4 or 5 AEs, suggesting a manageable safety profile for afatinib.
The data also indicated that among the 12 patients who solely received consolidation afatinib, the median PFS was only 2.9 months post-treatment discontinuation, with most experiencing disease progression. Treatment discontinuation reasons varied, including toxicity and completion of the treatment course.
Future Considerations
The findings from the ASCENT trial pose critical questions for future research. While targeted TKIs have established their role in the treatment of metastatic oncogene-driven NSCLC, their application in locally advanced cases remains less understood. The authors of the study prompted further inquiry into the optimal timing for TKI administration—whether it is more effective in the neoadjuvant or adjuvant setting.
Additionally, the trial’s limitations regarding the distinct roles of induction and consolidation therapy with TKIs signal a need for further investigation. Establishing a clearer understanding of these modalities may pave the way for more tailored and effective treatment protocols in the future.
Conclusion
The ASCENT trial serves as a landmark study in the evolving landscape of EGFR-mutant NSCLC treatment. It highlights both the potential for long-term disease control with afatinib and the challenges that remain in optimizing therapeutic strategies. As researchers strive to refine treatment paradigms, the insights gleaned from this trial will undoubtedly influence future investigations aimed at improving patient outcomes.
- Takeaways:
- The ASCENT trial explores afatinib’s role in treating EGFR-mutant NSCLC alongside cCRT.
- A 63% overall response rate was observed, with promising long-term survival outcomes.
- Adverse events were manageable, though challenges remain in treatment optimization.
- Future research should focus on the timing and integration of TKI therapies in treatment protocols.
Read more → www.ajmc.com